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Abstract
Background: A high-sensitivity DNA microarray platform requiring nanograms of RNA input facilitates the
application of transcriptome analysis to individual skeletal muscle (SM) tissue samples. Culturing myotubes from
SM-biopsies enables investigating transcriptional defects and assaying therapeutic strategies. This study compares
the transcriptome of aneurally cultured human SM cells versus that of tissue biopsies.
Results: We used the Illumina expression BeadChips to determine the transcriptomic differences between tissue
and cultured SM samples from five individuals. Changes in the expression of several genes were confirmed by
QuantiGene Plex assay or reverse transcription real-time PCR. In cultured myotubes compared to the tissue, 1216
genes were regulated: 583 down and 633 up. Gene ontology analysis showed that downregulated genes were
mainly associated with cytoplasm, particularly mitochondria, and involved in metabolism and the muscle-system/
contraction process. Upregulated genes were predominantly related to cytoplasm, endoplasmic reticulum, and
extracellular matrix. The most significantly regulated pathway was mitochondrial dysfunction. Apoptosis genes were
also modulated. Among the most downregulated genes detected in this study were genes encoding metabolic
proteins AMPD1, PYGM, CPT1B and UCP3, muscle-system proteins TMOD4, MYBPC1, MYOZ1 and XIRP2, the
proteolytic CAPN3 and the myogenic regulator MYF6. Coordinated reduced expression of five members of the
GIMAP gene family, which form a cluster on chromosome 7, was shown, and the GIMAP4-reduction was validated.
Within the most upregulated group were genes encoding senescence/apoptosis-related proteins CDKN1A and
KIAA1199 and potential regulatory factors HIF1A, TOP2A and CCDC80.
Conclusions: Cultured muscle cells display reductive metabolic and muscle-system transcriptome adaptations as
observed in muscle atrophy and they activate tissue-remodeling and senescence/apoptosis processes.
Background
Oligonucleotide microarrays can reveal gene expression
profiles of SM tissue and provide valuable insight into
molecular pathways involved in pathogenesis or abnor-
mally regulated in disease. Various human disorders
that affect the SM tissue have been analyzed using
microarray technology, including disuse atrophy [1],
myositis [2,3], Duchenne muscular dystrophy (DMD)
[4-6] and others [7-9].
One of the limitations of applying microarray analyses
to such context is the amount of tissue material needed
[10]. For SM studies, genome-wide expression profiling
has in some cases been applied to pooled samples from
multiple patients [4,7]; in others, microarrays with a
restricted number of genes were used [2,6,8,9]. The pos-
sibility of performing whole transcriptome microarray
analysis on small amounts of tissue material facilitates
its application to tissue samples from individual subjects.
The culturing of myotubes from SM biopsies opens an
alternative to examine transcriptional defects with
microarrays and enables therapeutic strategies to be
assayed. SM cell cultures can be established by the
explant technique [11], which is based on the presence
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of myogenic progenitors, the satellite cells [12]. Satellite
cells are not committed to fiber type lineages [13,14].
When satellite cells are stimulated with growth factors,
they generate myoblasts, which can replicate a limited
number of times and be induced to fuse and form mul-
tinucleated myotubes. The drawback of cell cultures in
general is that cells change their phenotype, which may
alter the expression of certain genes and compromise
the phenotypic expression of the disease. Indeed, aneu-
rally cultured human SM cells remain relatively imma-
ture as shown in studies of the protein isoform pattern
[14-16] and microarray analysis of the transcriptome
[17].
There were no data on transcriptome differences
between cultured and tissue human SM cells. We
deployed an automated high-sensitivity microarray plat-
form to identify genes differentially expressed between
aneurally cultured myotubes derived from human SM
biopsies by the explant technique and the SM tissue
samples. We provide insight into the phenotype of the
cultured human SM, which is a valuable cell model for
pathogenesis studies and therapeutic assays.
Methods
Skeletal muscle specimens and cultures
Paravertebral muscles biopsies were obtained from five
subjects: females of age 12-15 years devoid of neuro-
muscular disease during surgery for idiopathic scoliosis.
Informed consent and approval from the Ethics Com-
mittee of the Hospital Sant Joan de Déu (Barcelona) was
obtained. Biopsies were embedded into RNAlater for
RNA extraction or into cell culture medium. Cultures
were prepared through an explant technique [11,17].
Briefly, SM biopsy pieces were dissected under a stereo-
microscope; fat, connective tissue and blood were
removed; and the pieces were frozen in DMEM medium
with 25% fetal bovine serum (FBS) and 6% DMSO. To
set up the culture, first the biopsy pieces were spaced
embedded in a semi-solid matrix, composed of 5 ml of
DMEM/M-199 medium (3:1) with 37.5% FBS and 1.25
ml of human plasma (Sigma-Aldrich, St. Louis, MO,
USA), overspread onto tissue culture plates, which were
then incubated for 6 to 8 days to permit fibroblast out-
growth. The biopsy pieces were then removed from the
matrix with forceps under the stereomicroscope, dis-
sected and embedded in a matrix, composed of 1 ml of
human plasma and 2 ml of 1.5% gelatin, spotted and
stuck onto new dishes and overlaid with DMEM/M-199
medium (3:1) with 10% FBS, 10 μg/ml insulin, 4 mM
glutamine, 25 ng/ml fibroblast growth factor, and 10 ng/
ml epidermal growth factor, for 5 to 7 days to permit
myoblast proliferation and migration. After myoblast
generation, the biopsy pieces were removed, and even-
tually re-explanted, and myoblast monolayers were
dissociated with trypsin and subcultured. Myogenic cells
from the same explant were subjected to limited conse-
cutive subcultures to avoid differences resulting from
senescence [17]. Myotubes were derived from confluent
myoblast cultures; immediately after initiation of myo-
blast fusion, medium was replaced by DMEM/M-199
medium (3:1) with 10% FBS and 10 μg/ml insulin, to
further stimulate differentiation. Myotubes were used 7
days later. Myotube preparations were labeled B19, B22,
B24, B25 and B26.
Immunocytochemistry
Cells grown on coverslips were fixed in 4% paraformal-
dehyde in PBS for 15 min, then washed in PBS, and
incubated for 10 min in PBS containing 50 mM NH4Cl,
10 min in PBS containing 20 mM glycine, 10 min in
PBS containing 0.1% Triton X-100 and 30 min in PBS
containing 10% FBS. Subsequently coverslips were incu-
bated for 1 h at room temperature with a rabbit anti-
desmin antibody (1:100; AB907 Millipore, Billerica, MA,
USA). Primary antibody was detected with an Alexa
Fluor-488 goat anti-rabbit antibody (1:500; Molecular
Probes, Eugene, OR, USA). Both primary and secondary
antibodies were diluted in blocking solution. Nuclei
were stained with Hoescht (1 μg/ml) during secondary
antibody incubation. After staining, samples were
mounted on Mowiol mounting medium and analyzed
with a Leica TCS SP2 confocal microscope. Images were
processed using Photoshop CS software (Adobe Corp,
San Jose, CA, USA). From 200 to 500 nuclei in each of
the 5 myotube cultures were analyzed with ImageJ (Ras-
band WS, ImageJ, National Institutes of Health,
Bethesda, MD, USA, http://rsb.info.nih.gov/ij/ and the
mean ± SD values of the percentage of nuclei located in
desmin-labeled myotubes were calculated.
Gene expression analysis
Ten samples, 5 from cultured SM cells, and 5 from SM
biopsies were analyzed by DNA microarrays. Total RNA
was extracted from SM biopsies with RNeasy fibrous tis-
sue kit and homogenized using a TissueLyser, and from
cultured myotubes with RNeasy kit (Qiagen, Valencia,
CA, USA), with the same DNase treatment than in the
RNeasy fibrous tissue kit, and homogenized with a Poly-
tron. RNA samples were quantified with the RiboGreen
RNA Quantification Kit (Molecular Probes), and moni-
tored with the Agilent 2100 Bioanalyzer, to check high-
quality RNA (RNA integrity = 8). We used HumanRef-8
v2.0 Expression BeadChips (Illumina, San Diego, CA,
USA), which comprise probes to interrogate 22200 tran-
scripts, based on the curated content of the NCBI Refer-
ence Sequence database, release 17.
An aliquot of 150 ng of total RNA was used to pro-
duce double-stranded cDNA, followed by transcription
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in vitro, and by cRNA labeling with biotin using the
TotalPrep RNA Amplification kit (Applied Biosystems/
Ambion, Austin, TX, USA) recommended by Illumina.
This method is based on the protocol developed in J.
Eberwine’s laboratory [18]. The procedure consists of
reverse transcription with an oligo(dT) primer bearing a
T7 promoter using a reverse transcriptase engineered to
produce high yields of first strand cDNA. The reverse
transcriptase catalyzes the synthesis of full-length cDNA
which then undergoes second strand synthesis and
clean-up to become a template for in vitro transcription
(IVT) with T7 RNA Polymerase. The IVT, along with
biotin UTP, is used to generate hundreds to thousands
of biotinylated, antisense RNA copies of each mRNA.
These procedures were performed on an automated sys-
tem primarily developed for the preparation of samples
for Affymetrix arrays [19], which we adapted for the
Illumina procedure. It is composed by a Microlab Star
liquid handling system (Hamilton, Bonaduz, Switzer-
land) for reagent and sample pipetting and mixing,
coupled with a thermocycler TRobot (Biometra, Goet-
tingen, Germany) for incubations, and a microtiter plate
reader SpectraMax M2 (Molecular Devices, Sunnyvale,
CA, USA) for nucleic acids quantification with Ribo-
Green assay. The 10 samples analyzed in the present
experiment were processed in a single robotic session.
The labeled-cRNAs thus produced were measured with
the Agilent 2100 Bioanalyzer to control for length. All
cRNA sizes were close to 1200 nt and therefore eligible
for hybridization onto the microarrays. Then, 750 ng of
labeled-cRNAs was added to the hybridization mix,
which contained control oligonucleotides in hybridiza-
tion buffer. Then, 15 μl of each hybridization mix was
dispensed on the BeadArrays. After hybridization (16 h,
58°C), the arrays were washed to remove non-hybridized
material and were stained with streptavidin-Cy3, which
bound to biotin. Scanning was performed using the Bea-
dArray Reader, which provided intensity values for all
transcripts. Bead redundancy allowed the calculation of
a detection p-value which served at declaring the tran-
scripts “significantly detected” or not. Signal intensities
were extracted and summarized in the BeadStudio soft-
ware. Data were expressed as absolute intensities, to
which we applied a background correction. Background
was calculated for each array by the average signal of
the negative control probes. All microarray experiments
were run at the same time. The Illumina HumanRef-8
BeadChip is a glass slide comprising 8 identical microar-
rays. We therefore used 2 slides for this experiment. To
minimize possible batch effect that can occur between
the two glass slides, we randomized the sample distribu-
tion in the following order: in one slide A (B19 in vitro),
B (B26 in vitro), C (B25 in vivo), D (B24 in vitro), E
(B24 in vivo), F (B22 in vivo), G (B26 in vivo) and H
(B25 in vitro) and in the other slide A (B19 in vivo) and
B (B22 in vitro). “In vitro” stands for cultured myotubes
and “in vivo” means SM tissue biopsies. As shown in a
recent study [20], randomization on Illumina slides
greatly improves the results reducing the number of
possible false positive occurrences that would lead to a
misinterpretation of the data. Microarray data files have
been deposited in GEO Omnibus [http://www.ncbi.nlm.
nih.gov/geo/ GEO accession number GSE17503].
QuantiGene Plex 2.0 assay (Panomics/Affymetrix, Fre-
mont, CA, USA) was used for confirmation of the
microarray analysis. The advantage of this assay is that
no RNA amplification is needed, unlike microarrays or
quantitative PCR. A comparison to other gene expres-
sion platforms in the frame of the MAQC project
demonstrated the sensitivity and accuracy of Quanti-
Gene techniques [21]. This technology uses three sets of
pooled oligonucleotides that function to capture, provide
binding sites for signal amplification molecules, and sta-
bilize the mRNA of interest. The capture extender (CE)
pool contains oligonucleotides that are complementary
to the mRNA of interest and to capture probes (CPs)
covalently linked to carboxylated fluorescent-encoded
micro spheres (Luminex, Austin, TX, USA). The label
extender (LE) pool has oligonucleotides that contain
sequences complementary to the mRNA of interest and
to the amplifier molecules which carry a streptavidin
phycoerythrin (SAPE) conjugate. The blocker (BL) pool
contains oligonucleotides that are complementary to the
mRNA where neither CE nor LE bind and it protects
the mRNA by maintaining an intact RNA-DNA hybrid.
The micro spheres (or beads) thus prepared are ana-
lyzed with a Luminex reader, which utilizes two lasers,
the first for bead identification, measuring the fluores-
cent signal specific to each bead type, and the second
for mRNA quantification, determining the fluorescence
level of SAPE and therefore the expression level of the
transcript. The assay was performed according to the
manufacturer’s instructions, accessible at: http://
panomics.com/downloads/
UM13075_RevB_QGP2_080430.pdf. Briefly, the RNAs
extracted from tissue and cell samples were deposited
on a 96-well plate along with the QuantiGene hybridiza-
tion solution (containing RNase-free water, lysis mix-
ture, blocking reagent, proteinase K, capture beads and
probe set). The hybridization plate was then sealed and
placed in a shaking incubator (Vortemp 56 Shaker/Incu-
bator, Labnet International, Inc., Woodbridge, NJ, USA)
at 54°C and 600 rpm for overnight hybridization (18-22
h). After centrifugation to remove condensation, the
hybridization mixture was transferred to a pre-wetted
filter plate, where the mixture was filtered and washed
three times in wash buffer. All washing steps were per-
formed with a MultiScreen Vacuum Manifold
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(Millipore) at low pressure, and after the final wash, the
filter plate bottom was blotted to remove any remaining
liquid to prevent leakage. The samples were then incu-
bated successively in three working solutions: pre-ampli-
fier and amplifier, biotinylated probes and SAPE. Two
washes were performed between each incubation to
remove unbound reagents. The plate was covered with
aluminum foil during SAPE incubation to prevent photo
bleaching. For Luminex measurement, after a calibration
of the Luminex, the plate was placed in the instrument.
Prior to the measurement, each bead type was identified
in the Luminex software in order to specify to which
transcripts the beads corresponded. At the start of the
measurement, the content of each well was aspirated
and pushed towards the lasers. As occurs in a flow cyt-
ometer, the beads passed successively in front of the
two lasers. Beads were identified, and fluorescent signals
were measured. The final outcome was a raw data file
containing signal intensity and background level for
each gene in each sample. Data were analyzed using the
transferrin receptor (TFRC) gene as the reference gene,
since its expression was similar within the two examined
groups, cultured myotubes and SM biopsies.
For reverse transcription (RT) and real-time PCR, an
aliquot of 0.5 μg of total RNA was retro-transcribed
(RT) with TaqMan reverse transcription reagents from
Applied Biosystems (Foster City, CA, USA) using ran-
dom hexamers and in a 25 μl total volume reaction.
Real-time PCR was performed on 1 μl of the RT reac-
tion mixture with the TaqMan universal PCR master
mix and TaqMan Gene Expression Assays using the
ABI PRISM 7700 sequence detection system. Probes for
PYGM (Hs00194493_m1), UCP3 (Hs00243297_m1),
THY1 (Hs00264235_s1) and B2M (Hs99999907_m1)
were from Applied Biosystems. The threshold cycle (Ct)
values of the reference probe beta-2 microglobulin
(B2M) were subtracted from each target probe Ct values
(ΔCt), the ΔCt values of the SM biopsies were sub-
tracted from the ΔCt values of myotube cultures. Data
were expressed as mean values of 2-ΔΔCT for upregu-
lated genes and 1/2-ΔΔCT for downregulated ones and
the significance of differences was estimated by a paired
t-test.
Statistical analysis and filtering
After the scanning of the microarrays, BeadStudio gen-
erated a dendrogram to control for the sample cluster-
ing. Subsequent steps of quality control (QC), statistical
analysis and filtering of microarray data were carried
out with GeneSpring GX software v10.0.2 (Agilent
Technologies, Santa Clara, CA, USA). Raw data with
background subtracted were loaded from Illumina Bead-
Studio to GeneSpring GX. This step was followed by
quantile normalization and log2 transformation. The
samples were then grouped into two conditions which
we called “in vitro“ and “in vivo“, corresponding respec-
tively to the SM cultures and the tissue biopsies. Gene-
Spring GX was used as the first step for QC of data on
all the samples with two unsupervised methods, Pearson
correlation and Principal Component Analysis (PCA).
The PCA vector space transformation was used to
reduce multidimensional data sets to lower dimensions
for analysis to assess the behavior of the samples and to
identify or confirm possible outliers. Within the quality
control step, Genespring GX enables to compute the 3
first principal components. The percentage of total var-
iance that each of these 3 principal components capture
is shown in the legend of Additional File 1.
To assess which genes were differentially expressed
between the two conditions examined, we performed a
corrected paired t-test on all probes. Because of the
small number of biological replicates, we used the Ben-
jamini-Hochberg false discovery rate (FDR) method con-
trolling for false positives, in order to select genes with
the lowest FDR. This method is less stringent than
other corrections such as the Bonferroni, and provides a
good balance between discovery of statistically signifi-
cant genes and limitation of false positive occurrences.
A corrected p-value cutoff of 0.01 was used to select the
regulated genes with the lowest FDR. A fold change
value was also computed by GeneSpring GX to assess
the level and the direction of the gene regulation. Fold
change was calculated as the absolute ratio of normal-
ized intensities between the mean values of the samples
in the two conditions, cultured myotubes and SM tissue
biopsy, grouped.
Data from QuantiGene Plex were also loaded into
GeneSpring GX software. Originally GeneSpring GX
was designed for gene expression microarray experi-
ments and uses the main commercially available arrays
(Affymetrix, Illumina, Agilent and CodeLink). However,
it is possible to configure a “custom” array. The Quanti-
Gene Plex assay was therefore configured in GeneSpring
GX. After normalization to the TFRC control gene, data
were log2 transformed, and significance of differential
expression was assessed by a paired t-test.
Bioinformatic analysis
Functional annotation and classification analysis was
also carried out with GeneSpring GX program, running
a Gene Ontology (GO) analysis on the gene set selected
with the statistical analysis described above. GeneSpring
GX computed a p-value to quantify the significance in
the GO analysis. This p-value is the probability that a
random subset of x genes drawn from the total set of n
genes will have y or more entities containing a given
GO term. This probability is described by a standard
hypergeometric distribution. GeneSpring GX uses the
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hypergeometric formula from first principles to compute
this probability. Since a large number of hypotheses will
be tested, some form of correction is required. Gene-
Spring GX addresses this issue using the Benjamini-
Yekutieli correction, which takes into account the
dependency among the GO terms. In the GO analysis
done in GeneSpring GX, a low p-value therefore implies
that the given GO term is enriched. The Gene Ontology
data in GX 10.0.2 is compiled from version 1.2 of OBO
(Open Biomedical Ontologies).
Data were interpreted using Ingenuity Pathways Ana-
lysis (IPA) (Ingenuity Systems, Redwood City, CA, USA)
http://www.ingenuity.com. The list of significantly regu-
lated genes selected by the microarray analysis described
above was loaded in IPA with the following criteria:
Reference set: HumanRef-8 v2.0; Direct and Indirect
relationships included; filtered by species (human), and
in a second round, by tissue (skeletal muscle). Then IPA
computed the data to generate significant networks of
genes that are associated with particular biological func-
tions, diseases, and molecular processes. It showed also
the canonical pathways stimulated by the experiment.
IPA used the right-tailed Fisher’s exact test to extract
significant pathways. IPA canonical pathways are well-
characterized metabolic and cell-signaling pathways
coming from articles, reviews, books, and KEGG Ligand.
Gene cluster analysis was performed with the REEF
(REgionally Enriched Features in genomes) program,
which scans the genome using a sliding window
approach, and calculates the statistical significance of
each window using the hypergeometric distribution and
the false discovery rate [22].
Results
Genes differentially expressed in cultured versus skeletal
muscle tissue
Microarray analyses were performed on the 5 SM cul-
tures and the 5 SM biopsies. We confirmed that myo-
tubes were the prevalent cell type in each of the SM
cultures by immunostaining for desmin, a muscle-speci-
fic intermediate filament protein [23] (Additional file 1,
Figure S1). Most of the Hoescht-stained nuclei were
located in desmin-labeled myotubes: B19 (78.3 ± 3.12%),
B22 (61.4 ± 6.60%), B24 (61.8 ± 8.36%), B25 (83.6 ±
14.50%) and B26 (79.7 ± 5.05%). The microarray analysis
showed that in the cultured myotubes compared to the
tissue biopsies 1260 transcripts, which correspond to
1216 nuclear genes, were differentially expressed (selec-
tion criteria: absolute fold-change value > 2 with a cor-
rected p-value of p < 0.01). Of these, 583 were
downregulated and 633 were upregulated. The complete
list of regulated genes is shown in Additional file 2,
Table S1. On the basis of the correlation analysis per-
formed, Additional file 3, Figure S2 shows that the
samples were clearly separated based on their condition
cultured myotubes or SM biopsy. The dendrogram also
illustrates that the paired samples were differently dis-
tributed in the two conditions. PCA and correlation
matrix procedures show that the two experimental con-
ditions were well separated and there were no particular
outliers in the experiment. Moreover, they highlight that
the variability was higher within the SM culture group
(in vitro). Pearson coefficients are also provided; the
average Pearson coefficient was 0.97 for the SM biopsies
and 0.93 for the SM cultures. PCA, correlation matrix
and dendrogram also confirmed that there was no sig-
nificant batch effect between the two Illumina slides in
our experiment. In an attempt to restrict differentially
expressed genes to those expressed in SM, microarray
data were filtered according to the IPA knowledge-base,
so that genes expressed in SM were selected. SM-speci-
ficity is shown in Additional file 2, Table S1. IPA knowl-
edge about mRNA expression in tissues is based on two
sources: the GNF body atlas [24], and literature findings.
Among the downregulated genes, 384 passed this filter
along with 318 of the upregulated genes. The filtering
served as a means for identifying genes that are
expressed in other cell types, present in the SM tissue,
within the most regulated genes. For instance, hemoglo-
bin HBB and HBA2 genes, which are mainly expressed
in erythroid cells [25], from the most downregulated
group and the THY1 gene, which is mainly expressed in
human fibroblasts, neurons and endothelial cells [26],
from the most upregulated group. Remarkably, the
ratios between the normalized signal of the THY1 and
desmin gene markers in the SM cultures were in a nar-
row range: B19 (1.94), B22 (1.12), B24 (1.42), B25 (1.28)
and B26 (1.44), again indicating that fibroblast presence
did not vary widely within SM cultures. However, the
THY1/desmin ratios were from 1.3- to 3.2-fold higher
in the SM cultures than in the SM biopsies.
The complete set of differentially expressed genes
were classified, separately for downregulated and upre-
gulated genes, according to GO (Additional file 4, Table
S2A). With respect to the cellular component, genes
that were downregulated in cultured myotubes were
mainly associated with cytoplasm and enriched in mito-
chondria. The over-represented biological processes
were metabolism, with the largest group of regulated
genes, and muscle-system/contraction. With respect to
metabolism, genes were mainly involved in the genera-
tion of precursor metabolites and energy, cellular
respiration and oxidative phosphorylation; quinone
cofactor metabolism was also affected. The most aug-
mented molecular function was oxidoreductase activity.
Among the genes that were upregulated in cultured
myotubes, the enriched cellular components were cyto-
plasm (with the largest group associated with
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endoplasmic reticulum (ER)) and the extracellular
matrix. The enriched molecular function here was oligo-
saccharyl transferase activity. The augmented biological
process was modification of an amino acid residue in a
protein: N-linked posttranslational glycosylation at
asparagine residues. GO annotations of the SM-
expressed subset of downregulated genes (Additional file
4, Table S2B) did not differ greatly from those of the
whole gene set, except for the occurrence of the follow-
ing over-represented GO annotations: cytoskeletal pro-
tein binding (molecular function); fatty acid beta-
oxidation and organic acid metabolism-related terms
(metabolic processes); and muscle development (biologi-
cal process). There was no GO annotation enrichment
within the upregulated SM-expressed subset for molecu-
lar function and biological process categories (Addi-
tional file 4, Table S2B).
The most regulated SM-expressed genes on the basis
of the fold-change are listed in Table 1. This selection
was performed on the whole set of 1260 regulated tran-
scripts (data not shown) before the replicated genes
were removed. In Additional file 5, Table S3, the stan-
dard deviation for each of these genes, based on the
normalized signals, is shown. A closer examination of
the downregulated group reveals several muscle-system
genes encoding proteins of myofilaments MYL3; asso-
ciated/regulatory proteins TMOD4, MYBPC1, MYOZ3,
MYOZ1, NRAP and XIRP2; the regulator of the muscle
sarcomere CAPN3 [27]; and calcium-related proteins
CASQ1 and S100A1. Genes encoding metabolic proteins
are included in this group: LPL, CPT1B, PYGM and
AMPD1. Potential regulatory factors are also present:
members of the ankyrin repeat- and SOCS (suppressor
of cytokine signaling) box-containing protein (ASB)
family, ASB10 and ASB12; members of the muscle
ankyrin repeat protein (MARP) family, ANKRD2 and
ANKRD23; and the transcription factor MYF6. The ion
channels CLIC5 and KCNA7, the transporters AQP4
and MB, and the neurite outgrowth inhibitor RTN4 are
included. Other genes such as those encoding NIPS-
NAP3B, HHATL and MYOC have no defined function
in SM.
Among the most upregulated genes detected in this
study (Table 1) are well-known regulatory factors such
as CDKN1A/p21, TOP2A and HIF1A. Several genes are
related to the extracellular matrix, such as those encod-
ing: the Ca(2+)-binding proteoglycan SPOCK1; isoforms
of lysyl hydroxylase (PLOD3, PLOD2) [28], an enzyme
that catalyzes the formation of hydroxylysine in col-
lagens; CSGlcA-T, which is involved in the synthesis of
chondroitin sulphate as a glucuronyltransferase [29]; the
metalloproteinase MMP14; TIMP2, an inhibitor of the
metalloproteinase type IV collagenolytic activity [30]
and the protease inhibitor SERPINE2 [31]. The NFASC
gene, which promotes axon subcellular targeting and
synapse formation [32], was another highly induced
gene, suggesting stimulation of neuronal signaling. Two
genes are related to stress: the gene encoding the puta-
tive glutathione peroxidase GPX8, an enzyme involved
in protection against oxidative stress [33], and the
DNAJC10/ERDJ5 gene. The PTX3 gene is related to
inflammation [34]. Other genes are related to sphingo-
myelin metabolism such as those encoding: GBA, a lyso-
somal enzyme that catalyzes glucosylceramide
breakdown [35], and SGMS2, an enzyme that produces
sphingomyelin [36]. Finally, a group of genes encodes
proteins that either have an undefined (i.e.
TMEM200A), or an unknown function in the SM tissue
(KIAA1199, PSD3, CCDC80/URB/SSG1/DRO1 and
LPIN2).
We assessed the changed expression for 17 genes that
were selected as follows. Within the 10% most regulated
genes, including both downregulated and upregulated
groups, we selected genes that were involved in various
regulated biological functions (metabolism, muscle-sys-
tem/contraction and apoptosis), the GIMAP4 family
member, the transcription factors MYF6 and HIF1A and
other potential regulators such as TOP2A and CCDC80,
and THY1. We used the QuantiGene Plex assay to cor-
roborate most of the genes. This assay does not require
any RNA amplification, unlike microarrays or quantita-
tive PCR, and is both sensitive and accurate [21]. How-
ever, 3 of these genes were validated by the customary,
readily accessible RT and real-time PCR technique [17].
Differential expression was confirmed for all of the
selected genes (Table 2). Differences in downregulated
genes that were assessed with the QuantiGene Plex
assay were equivalent to or greater (less than 6-fold)
than those assessed with the microarray, as were the dif-
ferences assessed with RT and real-time PCR (12- or 20-
fold greater). In the latter case, increased expression of
the B2M control gene in SM cultures compared to SM
tissue (Additional file 2, Table S1), which was confirmed
by RT real-time PCR, may have contributed to increas-
ing the differences. In contrast, differences in upregu-
lated genes measured with the QuantiGene Plex assay
were smaller than those measured with the microarray
(1.7- to 7-fold). However, with THY1, the difference
assessed by RT and real-time PCR was similar.
Genome mapping
Since members of the same gene family or genes that
are coordinately expressed might form clusters on chro-
mosomes, we tested the possibility that coregulated
genes showed spatial clustering. We applied the Gene-
Spring GX program to the entire set of 1216 differen-
tially expressed genes to identify the chromosome and
genomic position. Of these genes, 983 had chromosome
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Table 1 Top regulated genes filtered by expression in skeletal muscle
Gene ID Gene Name Description FC
DOWNREGULATED
4151 MB myoglobin -2541
761 CA3 carbonic anhydrase III, muscle specific -2391
29765 TMOD4 tropomodulin 4 (muscle) -1564
4634 MYL3 myosin, light chain 3, alkali; ventricular, skeletal, slow -1529
844 CASQ1 calsequestrin 1 (fast-twitch, skeletal muscle) -1496
270 AMPD1 adenosine monophosphate deaminase 1 (isoform M) -1320
4604 MYBPC1 myosin binding protein C, slow type -1128
136371 ASB10 ankyrin repeat and SOCS box-containing 10 -869.2
91977 MYOZ3 myozenin 3 -841.6
4023 LPL lipoprotein lipase -608.5
58529 MYOZ1 myozenin 1 -546.7
53405 CLIC5 chloride intracellular channel 5 -504.7
6271 S100A1 S100 calcium binding protein A1 -366.4
57467 HHATL hedgehog acyltransferase-like -364.5
57142 RTN4 reticulon 4 -338.4
6123 RPL3L ribosomal protein L3-like -317.8
200539 ANKRD23 ankyrin repeat domain 23 -298.1
4892 NRAP nebulin-related anchoring protein -294.9
123722 FSD2 fibronectin type III and SPRY domain containing 2 -293.3
760 CA2 carbonic anhydrase II -290.2
5837 PYGM phosphorylase, glycogen; muscle (McArdle syndrome, glycogen storage disease type V) -277.4
84448 ABLIM2 actin binding LIM protein family, member 2 -276.9
4618 MYF6 myogenic factor 6 (herculin) -265.7
142689 ASB12 ankyrin repeat and SOCS box-containing 12 -228.6
339456 TMEM52 transmembrane protein 52 -217.2
129446 XIRP2 xin actin-binding repeat containing 2 -216.1
26287 ANKRD2 ankyrin repeat domain 2 (stretch responsive muscle) -200.5
712 C1QA complement component 1, q subcomponent, A chain -197.9
10840 ALDH1L1 aldehyde dehydrogenase 1 family, member L1 -196.1
9452 ITM2A integral membrane protein 2A -178.5
5104 SERPINA5 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5 -175.8
825 CAPN3 calpain 3, (p94) -164.2
4653 MYOC myocilin, trabecular meshwork inducible glucocorticoid response -162.9
55335 NIPSNAP3B nipsnap homolog 3B (C. elegans) -161.9
361 AQP4 aquaporin 4 -160.4
4129 MAOB monoamine oxidase B -158.9
1375 CPT1B carnitine palmitoyltransferase 1B (muscle) -151.4
3743 KCNA7 potassium voltage-gated channel, shaker-related subfamily, member 7 -137.9
UPREGULATED
57214 KIAA1199 KIAA1199 +1279
5806 PTX3 pentraxin-related gene, rapidly induced by IL-1 beta +491.7
1026 CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) +192.8
114801 TMEM200A transmembrane protein 200A +184.9
2335 FN1 fibronectin 1 +82.93/43.39D
23362 PSD3 pleckstrin and Sec7 domain containing 3 +82.63
124565 SLC38A10 solute carrier family 38, member 10 +68.68
7077 TIMP2 TIMP metallopeptidase inhibitor 2 +68.09
7153 TOP2A topoisomerase (DNA) II alpha 170kDa +43.58
8985 PLOD3 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 +43.02
6505 SLC1A1 solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1 +40.97
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annotations that were distributed throughout all chro-
mosomes (Figure 1A), although the highest number was
on chromosome 1. We applied the REEF program to
the whole set of 983 differentially expressed chromo-
some-annotated genes to search for local clustering.
Three gene clusters were recognized using the REEF
program (Figure 1B). The cluster on chromosome 7
(Figure 1C) contained the largest number of genes and
included five members of the GTPase of the immunity-
associated protein (GIMAP) gene family, plus ASB10
and CSGlcA-T. Except the CSGlcA-T gene, all genes in
the cluster are highly downregulated. The genes encod-
ing GIMAP4, GIMAP5, ASB10 and CSGlcA-T are
expressed in SM (Additional file 2, Table S1). No gene
families were detected in clusters on chromosomes 1
and 20.
Bioinformatic analysis and interpretation of microarray
expression data
To reveal regulated metabolic and signaling pathways
the complete set of differentially expressed genes was
analyzed by IPA. According to IPA, 10 signaling and 13
metabolic canonical pathways are regulated in myotubes
versus SM tissue (Table 3). The most regulated meta-
bolic pathways are related to mitochondria: the citrate
cycle, oxidative phosphorylation and ubiquinone
biosynthesis. Consequently, mitochondrial dysfunction is
the most regulated signaling pathway. Network analysis
of this pathway illustrates known interactions between
the identified genes and overall pathway downregulation
(Figure 2). Included genes are those encoding: compo-
nents of the oxidative phosphorylation system (most of
which are in complex I, some are components of com-
plexes II, III and IV and cytochrome c CYCS); UCP3, an
inner mitochondrial membrane transporter that dissi-
pates the proton gradient [37]; CPT1B, which is asso-
ciated with the outer mitochondrial membrane and
facilitates the mitochondrial import of long chain fatty
acids, and ACACB, which converts acetylCoA into mal-
onylCoA to inhibit CPT1B [38]; MAOB, an enzyme
involved in the degradation of biogenic amines [39]; the
pyruvate dehydrogenase E1-alpha subunit (PDHA); and
alpha-ketoglutarate dehydrogenase (KGDH). All these
genes are expressed in SM except the NDUFAB1,
NDUFA4, COX10 and UQCRB genes according to the
IPA knowledge-base. Additional regulated metabolic
pathways involve glucose, amino acid and monocar-
boxylic acid metabolism. Results were similar when the
subset of SM-expressed genes was analyzed. However,
the pathways One carbon pool by folate and Biosynth-
esis of steroids were not enriched, whereas the pathways
Fatty acid metabolism, Phenylalanine metabolism and
Table 1: Top regulated genes filtered by expression in skeletal muscle (Continued)
9663 LPIN2 lipin 2 +40.92
54480 CSGlcAT chondroitin sulfate glucuronyltransferase +39.96
338773 TMEM119 transmembrane protein 119 +38.12
5352 PLOD2 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 +36.07/25.77D
493869 GPX8 glutathione peroxidase 8 +35.9
3091 HIF1A hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) +34.89
115908 CTHRC1 collagen triple helix repeat containing 1 +33.74
8572 PDLIM4 PDZ and LIM domain 4 +31.9
151887 CCDC80 coiled-coil domain containing 80 +31.02/17.06D
4323 MMP14 matrix metallopeptidase 14 (membrane-inserted) +29.75
23114 NFASC neurofascin homolog (chicken) +26.53
55165 CEP55 centrosomal protein 55kDa +25.73
5270 SERPINE2 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 +24.59
54431 DNAJC10 DnaJ (Hsp40) homolog, subfamily C, member 10 +24.52
6695 SPOCK1 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1 +24.35
2629 GBA glucosidase, beta; acid (includes glucosylceramidase) +24.33
7421 VDR vitamin D (1,25- dihydroxyvitamin D3) receptor +23.83
4643 MYO1E myosin IE +23.46
166929 SGMS2 sphingomyelin synthase 2 +22.63
7058 THBS2 thrombospondin 2 +22.59
The list includes the 10% most differentially expressed genes in cultured myotubes compared to SM tissue. The set of the 1260 regulated gene transcripts,
including replicated genes, was selected on the basis of their expression in SM, according to the IPA knowledge-base and the fold-change and was ordered by
the magnitude of the fold change. For each gene, the fold change in gene expression was calculated between mean values in cultured myotubes versus SM
biopsy. Duplicated genes on the microarray are marked (D) and the two values are shown. The significance of differences was estimated by a Benjamini-
Hochberg corrected paired t-test (p < 0.01). The first column lists the ID for Entrez Gene, the second the gene name, the third the description of the gene and
the fourth the fold change (FC) with a negative symbol for downregulated genes and a positive symbol for upregulated genes.
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Glyoxylate, dicarboxylate metabolism were enriched
with -log(p-values) of 2.38, 2.13 and 1.81, respectively.
Other regulated signaling pathways in the complete set
of the differentially expressed genes relate to cell interac-
tion with the extracellular matrix (integrin signaling,
hepatic fibrosis), cell communication with its environ-
ment (caveolar-mediated endocytosis) and actin-cytoske-
leton signaling. In addition, circadian rhythm signaling
was altered, with five genes all downregulated. Finally,
apoptosis and the signaling of phosphatase and tensin
homolog (PTEN) (Figure 3) were regulated. PTEN
dephosphorylates the signaling lipid phosphatidylinositol
(3,4,5)-trisphosphate and affects cellular processes related
to cell proliferation, apoptosis and muscle contractility
[40]. All signaling pathways except the p53-pathway were
significantly and similarly regulated when the subset of
SM-expressed genes was analyzed (data not shown).
Discussion
Using the high-sensitivity Illumina microarray platform,
we identified changes in the human SM cell transcrip-
tome that were induced by tissue biopsy culture based
on the explant technique. More than one thousand
genes displayed differential expression between cultured
myotubes and SM tissue. A similar number of genes
were upregulated and downregulated: 65% and 50% of
the genes in each group, respectively, were expressed in
SM according to the IPA knowledge-base.
Ontology analysis of downregulated genes in SM cul-
tures revealed the following. In terms of their asso-
ciated cellular components, there was an over-
representation of genes encoding proteins located in
mitochondria. In terms of their associated cell process,
the genes that were enriched were involved in energy
metabolism and the muscle-system. In line with this,
the genes that had the most reduced expression
included those encoding key regulators of glycogenoly-
sis (PYGM), fatty acid oxidation (CPT1B) and preser-
vation of ATP formation (AMPD1). Various genes
involved in glycolysis, energy consumption (UCP3) and
oxidative phosphorylation (complexes I, II, III and IV)
were also repressed. IPA pathway analysis consistently
revealed that the majority of regulated metabolic genes
are involved in mitochondrial pathways of energy pro-
duction and the most regulated signaling pathway is
mitochondrial dysfunction. The highly downregulated
genes also included those that encode proteins asso-
ciated with myofilaments, calcium-binding proteins
and CAPN3, a muscle-specific calcium-activated nonly-
sosomal cysteine protease that contributes to sarco-
mere homeostasis [27]. Downregulated genes are slow-
type isoforms such as MYL3, MYBPC1 and MYOZ1
and isoforms that are predominantly expressed in fast-
type muscle fibers such as TMOD4, CASQ1 and
MYOZ3. Noteworthy, the lumbar paravertebral mus-
cles in humans are described as containing fiber types,
Table 2 Genes validated for differential expression
Gene ID Gene Name Description FCM FCV
29765 TMOD4 tropomodulin 4 (muscle) -1564 -3065*
270 AMPD1 adenosine monophosphate deaminase 1 (isoform M) -1320 -2799*
4604 MYBPC1 myosin binding protein C, slow type -1128 -1574*
58529 MYOZ1 myozenin 1 -546.7 -3449*
5837 PYGM phosphorylase, glycogen; muscle -277.4 -3444**
4618 MYF6 myogenic factor 6 (herculin) -265.7 -258.8*
129446 XIRP2 xin actin-binding repeat containing 2 -216.1 -498.5*
825 CAPN3 calpain 3, (p94) -164.2 -497.9*
1375 CPT1B carnitine palmitoyltransferase 1B (muscle) -151.4 -109.5*
7352 UCP3 uncoupling protein 3 (mitochondrial, proton carrier) -106.5 -2086**
55303 GIMAP4 GTPase, IMAP family member 4 -71.28 -146.3*
7070 THY1 Thy-1 cell surface antigen +16.67 +18.15*
151887 CCDC80 coiled-coil domain containing 80 +31.02/17.06D +7.04*
3091 HIF1A hypoxia-inducible factor 1, alpha subunit +34.89 +19.62*
7153 TOP2A topoisomerase (DNA) II alpha 170kDa +43.58 +5.83*
1026 CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) +192.8 +31.67*
57214 KIAA1199 KIAA1199 +1279 +370.6*
List of genes with changed expression as validated by RT and real-time PCR (PYGM, UCP3, THY1) or QuantiGene Plex (the remaining genes). For each targeted
gene, the expression was determined relative to the B2M (in RT and real-time PCR) or TFRC (in QuantiGene Plex) genes. Similar data were obtained with
QuantiGene Plex when the B2M gene was used as a control (data not shown). For each gene, the fold change in gene expression was calculated between mean
values in cultured myotubes versus SM biopsy. The significance of differences was estimated by a paired t-test: *p < 0.01 and **p < 0.005. The first, second and
third columns are as in Table 1, the fourth lists the fold change in the microarray (FCM) as in Table 1 and the fifth the fold change in the validation techniques
(FCV), with a negative symbol for downregulated genes and a positive symbol for upregulated genes. The Pearson correlation coefficient between FCM and FCV
values is 0.684 (including the two copies of the CCDC80 gene).
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type I (slow) and type II (fast), in similar proportions
[41,42]. The downregulation found in the metabolic
and muscle-system profile in SM cultures is consistent
with findings in several myopathies. For instance,
energy metabolism genes were the major group of
genes downregulated in human muscle by disuse atro-
phy [1], DMD [6,7], a-sarcoglycan deficiency [7] and
X-linked myotubular myopathy (XLMTM) [9].
Decreased expression of genes encoding muscle-sys-
tem/contraction associated or regulatory proteins was
observed in DMD [6] and XLMTM patients [9]. In
muscles of immobilized legs in patients [1], major
categories of downregulated genes were involved in
sarcomere structure and protein turnover (including
the CAPN3 gene). According to our data, the full phe-
notype of several muscle pathologies may not be
expressed in cultured muscle as the genes are
markedly downregulated. This includes PYGM-defi-
ciency (McArdle disease) [43]; lack of AMPD1, which
causes metabolic myopathy in humans [44]; and loss-
of-function mutations in the CAPN3 gene that have
been associated with limb-girdle muscular dystrophy
type 2A (LGMD2A) [27].
We identified potential regulators of SM function
among the most downregulated genes. Myf6/MRF4 is a
member of the family of myogenic regulatory factors
that includes MyoD, Myf5 and myogenin [45]. MRF4
expression is sufficient for conversion of fibroblasts to
myogenic lineage [46]. However, MRF4 did not stimu-
late myogenic differentiation in C2C12 cells, but cell
proliferation, in contrast to MyoD [47]. In addition, it
was inefficient at trans-activating contractile protein
genes, unlike MyoD and myogenin [46]. Various genes
encoding proteins that contain the ankyrin repeat struc-
tural motif were strongly downregulated, namely, the
ASB family members ASB10 and ASB12. ASBs are
implicated in various biological processes. For example,
ASB15 promotes muscle cell growth and stimulates pro-
tein synthesis [48], while ASB6 regulates components of
the insulin signaling pathway in adipocytes [49]. Two
members of the MARP family are also included:
ANKRD2 and ANKRD23. ANKRD2/Arpp appears to be
involved in sensing stress signals and linking these to
muscle gene regulation [50], and ANKRD23/DARP is
upregulated in insulin-resistant animals [51]. Abrogation
of the three MARP family members CARP, ANKRD2
and DARP in mice indicated a role in passive mechani-
cal behavior and in the regenerative response in muscle
[52].
In myotubes versus SM tissue, we found coordinated
reduced expression of five members of the GIMAP gene
family GIMAP1, GIMAP4, GIMAP5, GIMAP6 and
GIMAP7, which form a cluster on chromosome 7 and
participate in cell survival/death. Seven GIMAP genes
are functional: GIMAP1, GIMAP2, GIMAP4, GIMAP5,
GIMAP6, GIMAP7 and GIMAP8 [53]. The GIMAPS are
also called immune-associated nucleotide-binding pro-
teins and are considered cell survival regulators, with a
crucial role in lymphocytes: GIMAP5 is a key genetic
factor for lymphopenia in spontaneous BioBreeding rat
insulin-dependent diabetes and GIMAP4 has been
shown to accelerate programmed cell death in T-cells
[54]. In humans, the GIMAP family genes are expressed
in several tissues [54], although the highest expression
of most of these genes is in immune tissues. However,
to the best of our knowledge, this is the first description
of coordinate regulation of the expression of the genes
in this family, which indicates the participation of com-
mon mechanisms of transcriptional regulation: shared
control regions or the same control elements in each
gene.
Figure 1 Chromosome distribution and clusters of enriched
regulated genes. We used the GeneSpring GX program to obtain
the chromosome and genomic position of the 1216 differentially
expressed genes. Of these, 983 had chromosome annotations. Data
were analyzed with the REEF program, with a window width of 1
M, a shift of 200 k, a Q-value of 0.05 and a minimum number of
transcripts in clusters of 2. We used the REEF Reference file as
reference features. (A) The number of regulated genes is plotted
against each annotated chromosome. (B) The image shows the list
of chromosomes in the analyzed samples and a representation of
the position of clusters of enriched features as red squares. The last
line that corresponds to the Y chromosome is not listed. (C)
Selected genes in the cluster on chromosome 7 position 149600000
- 151000000 (p-value ≤ 2.117e-004). The first column lists the ID for
Entrez Gene, the second column the gene name, the third column
the gene description, the fourth column the fold change (FC) with
a negative symbol for downregulated genes and a positive symbol
for upregulated genes, and the fifth column indicates whether
these genes are expressed in SM according to IPA (positive symbol).
The cluster on chromosome 1, position 114200000 - 115800000 (p-
value ≤ 1.612e-004) was composed of OLFML3, DENND2C, AMPD1,
NRAS and CSDE1. The cluster on chromosome 20, position
29400000 - 30600000 (p-value ≤ 9.859e-005) included HM13,
COX4I2, MYLK2, C20orf160 and POFUT1.
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Figure 2 Mitochondrial dysfunction. Graphical representation of the differentially expressed genes in cultured myotubes compared to SM
tissue and their molecular relationships. Genes are represented as nodes. Node color indicates the direction of change of gene expression.
Downregulated genes are highlighted in green and upregulated genes in red. Color intensity corresponds to the magnitude of change. Nodes
are displayed using various shapes that represent the functional class of the gene product. The lines in between genes represent known
interactions. The pathway image was created using IPA software.
Figure 3 PTEN signaling pathway. Graphical representation of the differentially expressed genes in cultured myotubes compared to SM tissue
and their molecular relationships. Genes are represented as nodes. Node color indicates the direction of change of gene expression.
Downregulated genes are highlighted in green and upregulated genes in red. Color intensity corresponds to the magnitude of change. Nodes
are displayed using various shapes that represent the functional class of the gene product. The lines in between genes represent known
interactions. The pathway image was created using IPA software.
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In contrast, most of the upregulated genes in culture
were located in the ER and extracellular matrix on the
basis of the gene ontology analysis. Induced genes
included those involved in tissue remodeling, such as
genes encoding TIMP2, PLOD2 and PLOD3,
CSGlcAT, SERPINE2 and MMP14, all of which were
among the 10% most regulated. In addition, induced
genes included those involved in the formation of the
extracellular matrix, such as those encoding collagens,
laminins, fibronectin, integrins and proteoglycans. This
increase may be partially due to the enrichment of SM
cultures in fibroblasts compared to the tissue. This is
indicated by the increased expression, albeit less than
that of the 10% most regulated, of the THY1 gene,
which is expressed in fibroblasts, neurons and
endothelial cells. Myotubes may also contribute to this
increase in expression. In this regard, IPA analysis
revealed alteration of signaling pathways related to cell
interaction with the extracellular matrix/environment
in either the whole set or the subset of SM-filtered dif-
ferentially expressed genes. Remarkably, the proteogly-
can SPOCK1/SPARC/OSTEONECTIN gene was highly
induced. Upregulation of genes of the extracellular
matrix are common findings in muscle from DMD
[5-7], LGMD2A [8] and XLMTM patients [9], where it
is considered to reflect dystrophic changes. In some
cases, the SPARC gene is also included [5-7,9]. In our
SM cultures, the strong induction of DNAJC10/ERDJ5
gene expression suggests ER stress. DNAJC10/ERDJ5 is
abundant in secretory cells and induced during ER
stress [55]. It resides in ER, where secreted proteins
are translocated and encounter the folding machinery;
it has disulfide reductase activity and is involved in the
retro-translocation of misfolded proteins into cytosol
for degradation [56].
One of the most induced genes in culture is that
encoding CDKN1A/p21, an inhibitor of cell cycle pro-
gression, involved in the p53-dependent cellular senes-
cence, possibly mediating apoptosis execution [57].
Another highly induced gene encodes KIAA1199, a pro-
tein of undefined function that was identified as an
induced transcript in replicative senescent-induced renal
carcinoma cells by transfer of human chromosome 3
[58], and as a candidate for hearing loss [59]. These data
Table 3 Significantly regulated canonical pathways
Score Ratio Number of Focus Genes
Signaling Pathways
Mitochondrial Dysfunction 7.88 17.60% 30
Integrin Signaling 3.52 14.50% 28
Hepatic Fibrosis/Hepatic Stellate Cell Activation 2.38 14.10% 19
Caveolar-mediated Endocytosis 2.02 14.80% 12
Regulation of Actin-based Motility by Rho 1.77 13.00% 12
Actin Cytoskeleton Signaling 1.46 10.40% 23
Apoptosis Signaling 1.35 12.10% 11
Circadian Rhythm Signaling 1.31 15.60% 5
p53 Signaling 1.29 12.60% 11
PTEN Signaling 1.29 11.70% 11
Metabolic Pathways
Citrate Cycle 6.27 20.30% 12
Oxidative Phosphorylation 4.61 15.90% 25
Ubiquinone Biosynthesis 3.66 12.50% 13
Glycolysis/Gluconeogenesis 3.39 12.10% 17
Pyruvate Metabolism 3.15 9.66% 14
Tyrosine Metabolism 3.01 6.45% 12
Butanoate Metabolism 2.61 8.53% 11
One Carbon Pool by Folate 2.51 15.80% 6
Glycosaminoglycan Degradation 1.85 9.84% 6
Biosynthesis of Steroids 1.78 4.72% 6
Alanine and Aspartate Metabolism 1.67 9.30% 8
Propanoate Metabolism 1.54 7.14% 9
Lysine Degradation 1.34 6.25% 9
Canonical pathways that have significant associations with the whole set of regulated transcripts were assessed using IPA software. The scores are shown as -log
(p-value) in order to show positive numbers. The p-value was calculated by IPA using Fisher’s Exact Test. A threshold value of 1.3 was selected (p-value < 0.05).
The first column lists the signaling or metabolic pathways; the second the score value; the third the ratio, which represents the proportion of genes from the
dataset over the total number of genes in the pathway; and the fourth the number of focus genes.
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suggest that cultured muscle cells have activated a
senescence process that was not established in the mus-
cle tissue. Accordingly, the IPA analysis detected apop-
tosis as a regulated signaling pathway.
Among the most induced genes in SM cultures were
potential transcriptional regulators. These included the
gene encoding TOP2A, a DNA topoisomerase that is
associated with the RNA polymerase II holoenzyme and
is a required component of chromatin-dependent coac-
tivation [60], and the HIF1A/MOP1 gene, which
encodes the oxygen-sensitive alpha subunit of the tran-
scription factor hypoxia inducible factor-1 (HIF-1) that
forms a heterodimer with the beta subunit [61]. During
hypoxia the HIF1A protein is stabilized and activated.
The HIF1A gene is expressed constitutively in some cell
types, in others it is upregulated by hypoxia [62] or obe-
sity [63], although downregulation of mRNA levels by
hypoxia has also been reported in human fat cells [64].
With respect to hypoxia, we found that the MB gene
encoding the oxygen-binding myoglobin is one of the
most repressed in cultured SM cells. Among the targets
of HIF-1 [61], several genes showed increased expres-
sion in the SM cultures, such as the gene encoding the
protein related to vascular tone, ADM; to angiogenesis,
VEGFC; to glucose metabolism, ENO1; and the homo-
log of the pro-apoptotic BNIP3 protein BNIP3L/NIX
gene, which suggests increased activity of the HIF-1
transcription factor. However, other HIF-1 gene targets
involved in glucose metabolism [61] were not upregu-
lated. The overexpression of HIF1A factor is related to
local invasion and metastatic spread of tumor cells [61].
Thus, in SM cultures it may contribute to the activation
of the tissue remodeling process. Moreover, the HIF-1
factor has been related [65] to resistance to anoikis, a
programmed cell death induced by the loss of or inap-
propriate cell adhesion, in transformed epithelial cells
and it might also have this role in the SM cultures.
Two genes with potential involvement but no clear
role in metabolic control also showed increased expres-
sion in culture. One is the gene encoding CCDC80/
URB/SSG1/DRO1, which was identified as an upregu-
lated transcript in the adipose tissue of bombesin recep-
tor subtype-3 (BRS-3)-deficient mice displaying mild
late-onset obesity [66] and sensitizes cells to anoikis and
apoptosis [67]. The other is the gene encoding LPIN2,
which is a member of the lipin protein family that pos-
sesses phosphatidate phosphatase activity converting
phosphatidate to diacylglycerol. The function of the lat-
ter has not yet been defined and mutations of the gene
have been found in patients with Majeed syndrome, an
auto-inflammatory disorder [68].
In summary, our data show a reduction in the meta-
bolic and muscle-system transcriptome in the SM cul-
tures that may be due to inappropriate stimuli,
including the lack of innervation, the limited extracellu-
lar matrix molecules in SM cultures or other less-
defined stimuli such as circadian rhythm. The fact that
the tissue remodeling transcriptome is increased and
signaling pathways related to cell interaction with the
extracellular matrix/environment are regulated indicates
that a lack of appropriate matrix stimuli may be
involved, at least partly. The hypoxia response pathway,
which appears to be activated in SM cultures, may to
some extent trigger the tissue remodeling process.
Finally, the atrophic phenotype of cultured myotubes is
associated with the induction of genes related to apopto-
sis or anoikis and activation of the apoptosis signaling
pathway.
Conclusions
We show that a high-sensitivity microarray platform
enables analysis of SM tissue samples from individual
donors and derived cultures at whole transcriptome
level. Microarrays deliver the differential transcrip-
tome. The main findings are that SM cultures show
reductive metabolic and muscle-system transcriptome
adaptations as observed in muscle atrophy. The meta-
bolic reduction strongly affects key genes of the cata-
bolism of glucose and lipids and moderately and
extensively affects genes involved in mitochondrial
energy production. In contrast, SM cultures show aug-
mented tissue remodeling transcriptome and induction
of genes involved in the apoptosis or anoikis process.
Finally, the hypoxia-response pathway appears to parti-
cipate in this adaptation. Biological pathway analysis
by IPA provides insights into processes driven by the
culturing of SM such as mitochondrial dysfunction and
pathways related to cell interaction with the extracellu-
lar matrix and apoptosis. This study contributes to the
definition of the phenotype of the SM primary culture,
which is a valuable cell model that has key implica-
tions for the study of muscle pathogenesis and thera-
peutic assays.
Additional file 1: Figure S1. Immunostaining of muscle cultures with
the muscle-specific marker desmin. Cultured cells were
immunostained with desmin antibody. Then, to highlight nuclei, cells
were stained with Hoescht. Representative immunofluorescence
micrographs of SM cultures (A) B19, (B) B22, (C) B24, (D) B25 and (E) B26
are shown. Bar represents 50 μm. Most of the Hoescht-stained nuclei are
observed in desmin-labeled myotubes.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2164-11-
125-S1.JPEG ]
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Additional file 2: Table S1. Complete list of differentially expressed
genes after skeletal muscle culture. List of the complete set of genes
with differential expression in cultured myotubes compared to SM tissue.
Replicated genes, which occur more than once in the microarray, were
filtered and the first one appearing in the list was arbitrarily chosen. For
each gene, the fold change in gene expression was calculated as the
ratio between mean values in cultured myotubes versus SM biopsy. The
significance of differences was estimated by a Benjamini-Hochberg
corrected paired t-test (p < 0.01). The first column lists the ID for Entrez
Gene, the second column the gene name, the third column the
description of the gene, the fourth column the quality of expression (1)
or not (0) in skeletal muscle tissue (M), according to the IPA knowledge-
base, and the fifth column the fold change (FC) with a negative symbol
for downregulated genes and no symbol for upregulated genes.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2164-11-
125-S2.DOC ]
Additional file 3: Figure S2. Cluster and correlation analysis for
microarray data. A) Principal component analysis plot: X = principal
component 1, Y = principal component 2 and Z = principal component
3. The percentage of total variance that each principal component
captures is 95.9% for component 1, 2.15% for component 2 and 1.90%
for component 3. B) Absolute correlation dendrogram. C) Pearson
correlation matrix of all samples based on whole gene expression
profiles. D) Pearson correlation coefficients between all samples. A value
of 1 would mean a perfect correlation. In panels A and C, the samples
from the cultured myotube group (in vitro) are represented in red and
the samples from the SM tissue biopsies (in vivo) are represented in blue.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2164-11-
125-S3.JPEG ]
Additional file 4: Table S2. Most significantly regulated gene
ontologies. List of gene ontologies annotated from (A) the whole set or
(B) the subset filtered by expression in SM, on the basis of the IPA
knowledge-base, of downregulated and upregulated transcripts in
cultured myotubes compared to the SM tissue. We used the GO
database http://www.geneontology.org with the GeneSpring GX
software. GeneSpring GX calculated enrichment scores for GO terms
based on the list of regulated genes, and used enrichment scores and
Benjamini-Yekutieli (False Discovery Rate) corrected p-values to filter the
set of genes. GO terms that are enriched with a p-value cut-off of 0.1 are
shown. Less specific nodes in the GO hierarchy that contained the same
annotated genes as the stated most-specific nodes are not shown. The
first column lists the GO symbol, the second the GO term, the third the
corrected p-value and the fourth the count in the selection.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2164-11-
125-S4.DOC ]
Additional file 5: Table S3. Microarray data variability of the 10%
most skeletal muscle-filtered differentially expressed transcripts.
Log2 normalized intensities for each significantly regulated transcript (p
< 0.01 and fold change > 2) in each sample. The standard deviation for
each condition, in vitro and in vivo, is shown. A normalized intensity
value of 0 means that the raw signal was below the background and an
arbitrary value of 1 was assigned to enable the log2 transformation (log2
(1) = 0).
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